Developing Quantum MRI agents and polarization devices for assessing early patient response to treatment at the metabolic level
- Headquartered in: Ulm, Germany
- Founded in: 2015
- Sector: Biopharma, MedTech, Diagnostics, MRI Imaging
NVision has developed a quantum-based platform which polarizes natural metabolites, enabling these safe molecules to be used as an agent for imaging tumor metabolism via standard MRI. This safe imaging technology will provide clinicians worldwide unprecedented early insights into treatment efficacy, allowing non-responders to be moved onto another line of therapy more quickly. The company is based in Ulm, Germany, and active throughout the US and Europe.